Selectively replicating viral vectors

Cancer Gene Therapy

Volumn 9, Issue 12, 2002, Pages 987-1000

  Nemunaitis, John ^a   Edelman, Jeffrey ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; VIRUS VECTOR; ONYX 015; VIRUS VACCINE;

ADENOVIRUS; CANCER THERAPY; GENE THERAPY; HERPES SIMPLEX VIRUS; INFLUENZA VIRUS; LIVER TOXICITY; MORTALITY; MUMPS VIRUS; NEWCASTLE DISEASE PARAMYXOVIRUS; PRIORITY JOURNAL; REOVIRUS; REPLICON; REVIEW; SUICIDE GENE; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE; VIRUS MUTANT; VIRUS REPLICATION; ANIMAL; GENE VECTOR; GENETICS; HUMAN; ORTHOMYXOVIRUS; PROMOTER REGION; VIRUS; WEST NILE FLAVIVIRUS;

ADENOVIRIDAE; INFLUENZA VIRUS; MUMPS VIRUS; NEWCASTLE DISEASE VIRUS; PARAMYXOVIRIDAE; REOVIRUS SP.; SIMPLEXVIRUS; VACCINIA VIRUS;

ADENOVIRIDAE; ANIMALS; GENETIC VECTORS; HUMANS; MUMPS VIRUS; NEWCASTLE DISEASE VIRUS; ORTHOMYXOVIRIDAE; PROMOTER REGIONS (GENETICS); REOVIRIDAE; SIMPLEXVIRUS; VACCINIA VIRUS; VIRAL VACCINES; VIRUS REPLICATION; VIRUSES; WEST NILE VIRUS;

EID: 0036904082     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700547     Document Type: Review

References (256)

1. Nemunaitis J. Oncolytic viruses. Invest New Drugs. 1999;17: 375-386.
2. Seidman MA, Hogan SM, Wendland RL, et al. Variation in adenovirus receptor expression and adenovirus vector-mediated transgene expression at defined stages of the cell cycle. Mol Ther. 2001;4:13-21.
3. Kruyt FAE, Curiel DT. Toward a new generation of conditionally replicating adenoviruses: Pairing tumor selectivity with maximal oncolysis. Hum Gene Ther. 2002;13:485-495.
4. Ramachandra M, Rahman A, Zou A, et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Publ Group. 2001;19:1035-1041.
5. Hansen RM, Libnoch JA. Remission of chronic lymphocytic leukemia after smallpox vaccination. Arch Intern Med. 1978;138:1137-1138.
6. Bousser J, Zittoun R. Remission spontanee prolongee D-une leucemie lymphoide chromique. Nouv Rev Fr Hematol. 1965;5:498-501.
7. Vladimirskaia EB. A case of prolonged spontaneous remission in a patient with chronic lymphocytic leukemia. Probl Gematol Pereliv Krovi, 1962;7:51-54.
8. Weintraub LR. Lymphosarcoma: Remission associated with viral hepatitis. JAMA. 1969;24:1590-1591.
9. Sinkovics JG. Oncolytic viruses and viral oncolysates. Ann Immunol Hung. 1986;26:271-290.
10. Dock G. Influence of complicating diseases upon leukemia. Am J Med Sci. 1904;127:563-592.
11. Bierman HR, Hammon WMcD, Eddie BU, Meyer KF, Shimkin MB. The effect of viruses and bacterial infections on neoplastic diseases. Cancer Res. 1950;10:203-204 (abstract).
12. Blumming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet. 1971;II:105-106.
13. Taqi AM, Abdurraham MB, Yabubu AM, Fleming AF. Regression of Hodgkin's disease after measles. Lancet. 1981;I:1112.
14. Hernandez A. Obsevacion de un ease de enfermedad de Hodgkin, con regression de los sintomas e infartos ganglionares, post-sarampion. Rev Med Cubana. 1949;60:120-125.
15. Bierman HR, Crile DM, Dod KS. Remissions in leukemia of childhood following acute infectious disease: Staphylococcus and Streptococcus, varicella, and feline panleukopenia. Cancer. 1953;6:591-605.
16. Pelner L, Fowler GA, Nauts HC. Effects of concurrent infections and their toxins on the course of leukemia. Acta Med Scand. 1958;338:1-47 (supplement).
17. London RE. Multiple myeloma: Report of a case showing unusual remission lasting two years following severe hepatitis. Ann Intern Med. 1955;43:191-201.
18. De Pace NG. Case Report: Cervical cancer regression following rabies vaccination. Ginecologia. 1912;9:82.
19. Pack GT. Note of the experimental use of rabies vaccine for melanomatosis. Arch Dermatol Syph. 1950;62:694-695.
20. Southam. CM. Present status of oncolytic virus studies. Trans NY Acad. 1960;22:657-673.
21. Asada T. Treatment of human cancer with mumps virus. Cancer. 1974;34:1907-1928.
22. Yamanishi E, Takahashi M, Kurimura T, Ueda S, Minekawa Y. Studies on live mumps virus vaccine: III. Evaluation of newly developed live mumps virus vaccine. Biken J. 1970;13:157-161.
23. Moore AE. Carcinolytic viruses. In: Harris RJC, ed. Biological Approaches to Cancer Chemotherapy. New York: Academic Press; 1961:365-370.
24. Sinkovics JG, ed. Die Grundlagen der Vorusforschung. Budapest: Ungarische Akademie der Wissenchaften; 1956: 98-103, 235-247.
25. Harris JE, Sinkovics JG, eds. The Immunology of Malignant Disease. St. Louis: Mosby; 1976:180-182, 464-467, 475-478.
26. Hoster HA, Zanes RP, von Haam E. Studies in Hodgkin's syndrome. Cancer Res. 1949;9:473-480.
27. Brandt CD, Kim HW, Vargosko AJ, et al. Infections in 18,000 infants and children in controlled study of respiration tract disease. Adenovirus pathogenicity in relation to serologic type and illness syndrome. Am J Epidemiol. 1969;90:484-500.
28. Hierholzer JC. Adenoviruses types 4, 7, and 21 vaccines: Safety and immunogenicity. J Infect Dis. 1979;140:48-53.
29. Takafuji ET. Simultaneous administration of live, enteric coated adenovirus types 4, 7, and 21 vaccines: Safety and immunogenicity. J Infect Dis. 1979;140:48-53.
30. Green M, Wold WS, Mackey JK, Rigden P. Analysis of human tonsil and cancer DNA's and RNA's for DNA sequences in group C (serotypes 1, 2, 5 and 6) human adenoviruses. Proc Natl Acad Sci USA. 1979;76:6606-6610.
31. Lesoon-Wood LA, Kim WH, Kleinmann HK. Systematic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther. 1995;6:395-405.
32. Zhang W, Alemany R, Wang J. Safety evaluation of AdCMV p53 in vitro and in vivo. Hum Gene Ther. 1995;6:155-164.
33. Nielsen LL, Dell J, Maxwell E. Efficacy of p53 adenovirus mediated gene therapy against human breast cancer xenographs. Cancer Gene Ther. 1997;4:129-138.
34. Simon RH, Engelhardt JF, Yang Y. Adenovirus-mediated transfer of the CFRT gene to lung of non-human primates: Toxicity study. Hum Gene Ther. 1993;4:771-780.
35. Xu M, Kumar D, Srinivas S. Parental gene therapy with p53 inhibits human breast tumor in vivo through a bystander mechanism without evidence of toxicity. Hum Gene Ther. 1998;8:177-185.
36. Gomez-Foix AM, Coats WS, Baque S. Adenovirus-mediated transfer of the muscle flycogen phosporylate gene into hepatocytes confers altered regulation of glycogen. J Biol Chem. 1992;267:25129-25134.
37. Le Gal La Salle G, Robert JJ, Bernard S. An adenovirus vector for gene transfer into neurons and glia in the brain. Science. 1993;259:988-990.
38. Tursz T, Le Cesne A, Baldeyrou P. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer Inst. 1996;88:1857-1863.
39. Harvey BG, Worgall S, Ramirez M. Host responses to intradermal administration of a first generation replication deficient adenovirus vector to normal individuals. Am Soc Gene Ther. 1998;43a (Abstract 167).
40. Wodarz D. Viruses as antitumor weapons: Defining conditions for remission. Cancer Res. 2001;61:3501-3507.
41. Curiel DT. The development of conditionally replicative adenoviruses for cancer therapy. Clin Cancer Res. 2000;6:3395- 3399.
42. Yeh P, Perricaudet M. Advances in adenoviral vectors: From genetic engineering to biology. FASEB J. 1997;8:615-623.
43. Wold WSM, Doronin K, Toth K, Kuppuswamy M, Lichtenstein DL, Tollefson AE. Immune responses to adenovirus: Viral evasion mechanisms and their implications for the clinic. Curr Opin Immunol. 1999;11:380-386.
44. Mahr JA, Gooding LR. Immune evasion by adenoviruses. Immunol Rev. 1999;168:121-130.
45. Bai M, Harfe B, Freimuth P. Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. J Virol. 1993;67:5198-5205.
46. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins avB3 and avB5 promote adenovirus internalization but not virus attachment. Cell. 1993;73:309-319.
47. Huang S, Kamata T, Takada Y, Ruggezi ZM, Nemerow GR. Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J Virol. 1996;70:4502-4508.
48. Bergelson JM, et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320-1323.
49. Bergelson JM. Receptors mediating adenovirus attachment and internalization. Biochem Pharmacol. 1999;57:975-979.
50. Tomko RP, Xu R, Philipson L. HCAR and MCAR the human and mouse cellular receptors for subgroup C adenovirus and group B coxsackieviruses. Proc Natl Acad Sci USA. 1997;94: 3352-3356.
51. Davidson E, Diaz RM, Hart IR, Santis G, Marshall JF. Integrin a5B1-mediated adenovirus infection is enhanced by the integrin-activating antibody TS2/16. J Virol. 1997;71: 6204-6207.
52. FitzGerald DJ, Padmanabhan R, Pastan I, Wilingham MC. Adenovirus-induced release of epidermal growth factor and Pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytis. Cell. 1983;32:607-617.
53. 51Cr from KB cells at an acidic pH. J Biol Chem. 1984;259:14350-14353.
54. Greber UF, Webster P, Weber J, Helenius A. The role of the adenovirus protease on virus entry into cells. EMBO J. 1996;15:1766-1777.
55. Greber UF, et al. The role of the nuclear pore complex in adenovirus DNA entry. EMBO J. 1997;16:5998-6007.
56. Leopold PL, et al. Fluorescent visions: Dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells. Hum Gene Ther. 1998;9:367-378.
57. Wang K, Huang S, Kapoor-Munshi A, Nemerow G. Adenovirus internalization and infection require dynamin. J Virol. 1998;72:3455-3458.
58. Suomalainen M, et al. Microtubule-dependent plus-and-minus end-directed motilities are competing processes for nuclear targeting of adenovirus. J Cell Biol. 1999;144:657-672.
59. Wisnivesky JP, Leopold P, Crystal RG. Specific binding of adenovirus capcid to the nuclear envelope. Hum Gene Ther. 1999;10:2187-2195.
60. Leopold PL, et al. Dynein-microtubule - Mediated translocation of adenovirus serotype 5 occurs after endosomal lysis. Hum Gene Ther. 2000;11:151-165.
61. Saphire AC, Guan T, Schirmer EC, Nemerow GR, Gerace L. Nuclear import of adenovirus DNA in vitro involves the nuclear protein import pathway and hsc70. J Biol Chem. 2000;275:4298-4304.
62. Flint J, Shenk T. Viral transactivating proteins. Annu Rev Genet. 1997;31:177-212.
63. Bischoff JR, Kim DH, William A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373-376.
64. Rancourt C, et al. Interleukin-6 modulated conditionally replicative adenovirus as an antitumor/cytotoxic agent for cancer therapy. Clin Cancer Res. 1999;5:43-50.
65. Fueyo J, et al. A mutant oncolytic adenovirus targeting the RB pathway produces anti-glioma effect in vivo. Oncogene. 2000;19:2-12.
66. Doronin K, et al. Tumor-specific, replication-competent adenovirus vectors over expressing the adenovirus death protein. J Virol. 2000;74:6147-6155.
67. Howe J, et al. Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy. Mol Ther. 2000;2:485-495.
68. Heise C, et al. An adenovirus E1-A mutant that demonstrate potent and selective systemic anti-tumoral efficacy. Nat Med. 2000;6:1134-1139.
69. Kratzer F, Rosorius O, Hieger P, et al. The adenovirus type 5 EIB-55 K oncoprotein is a highly active shuttle protein and shuttling is independent of E4orf6 and Mdm2. Oncogene. 2000;19:850-857.
70. Harada J, Berk A. p53-independent and dependents requirements for EIB-55 kD in adenovirus type 5 replication. J Virol. 1999;73:5333-5344.
71. Curiel DT. Midkine promoter-based adenoviral vector gene therapy for pediatric solid tumors. Cancer Res. 2000;60: 4305-4310.
72. Gomez-Navarro J, Curiel DT. Conditionally replicative adenoviral vectors for cancer gene therapy. Lancet Oncol. 2000;1:148-158.
73. Kirn D. Clinical research results with dl1520 (ONYX-015), a replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther. 2001;8:89-98.
74. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57:2559-2563.
75. Alemany R, Lai S, Lou Y-C, Jan H, Fang X, Zhang W-W. Complementary adenoviral vectors for oncolysis. Cancer Gene Ther. 1999;6:21-25.
76. Braithwaite AW, Russel IA. Induction of cell death by adenovirus. Apoptosis. 2001;6:359-370.
77. Tollefson AE, Scaria A, Saha SK, Wold LJ, Wold WS. The 11,600-MW protein encoded by region E3 of adenovirus is expressed early but is greatly amplified at late stages of infection. J Virol. 1992;66:3633-3642.
78. Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE, Wold WS. Tumor-specific replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol. 2000;74:6147-6155.
79. McCart JA, Puhlmann M, Lee J, et al. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther. 2000;7:1217-1223.
80. Hawkins LK, Hermiston TW. Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the ADP region. Gene Ther. 2001;8:1131-1141.
81. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci USA. 1993;90:9552-9556.
82. Long BH, Fairchild CR. Paclitaxel inhibits progression of mitotic cells to GI phase by interference with spindle formation without affecting other microtubule functions anaphase and telephase. Cancer Res. 1994;54:4355-4361.
83. Adams JD, et al. Taxol: A history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr. 1993:141-147.
84. Kohn KW, Jackman J, O'Connor PM. Cell cycle control and cancer chemotherapy. J Cell Biochem. 1994;54:440-452.
85. Edelman MJ, Candra DR. Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol. 1996;37:385-393.
86. Ikeda K, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med. 1999;5:881-887.
87. Wold WS, Hermiston TW, Tollefson AE. Adenovirus proteins that subvent host defenses. Trends Microbiol. 1994;2:437-443.
88. Wold WS, Tollefson AE, Hermiston TW. E3 transcription unit of adenovirus. Curr Top Microbiol Immunol. 1995;199:237-274.
89. Horwitz MS, Tufariello J, Grunhaus A. Model system for studying the effects of adenovirus E3 gene on virulence in vivo. Curr Top Microbiol Immunol. 1995;199:195-211.
90. Lee MG, Abina MA, Haddada H, et al. The constitutive expression of the immunomodulatory gp 19 k protein in E1-E3 adenoviral vectors strongly reduces the host cytotoxic T-cell response against the vector. Gene Ther. 1995;2:256-262.
91. Bett AJ, Haddara W, Prevec L, et al. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA. 1994;91:8802-8806.
92. Lian Y. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci USA. 1997;94:2587-2592.
93. Elkon KB. Tumor necrosis factor α plays a central role in immune-mediated clearance of adenoviral vectors. Immunology. 1997;94:9814-9819.
94. Benihoud K. Efficient, repeated adenovirus-mediated gene transfer in mice lacking both tumor necrosis factor alpha and lymphotoxin α. J Virol. 1998;72:9514-9525.
95. Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Immunol. 2000;21:447-455 (Today).
96. Nash P, Barret JX, Cao S, et al. Immunomodulation by viruses: The myxoma virus story. Immunol Rev. 1999;168:103-120.
97. Smith GL, Symons JA, Khanna A, et al. Vaccinia virus immune evasion. Immunol Rev. 1997;159:137-154.
98. Smith VP, Bryant NA, Alcami A. Ectromelia, baccinia and cowpox viruses encode secreted interleukin-18-binding proteins. J Gen Virol. 2000;81:1223-1230.
99. Spriggs M. One step ahead the game: Viral immunomodulatory molecules. Annu Rev Immunol. 1996;14:101-130.
100. Saraiva M, Alcami A. CrmE, a novel soluble tumor necrosis factor receptor encoded by poxviruses. J Virol. 2001;75:226- 233.
101. Mahr JA, Gooding LR. Immune evasion by adenoviruses. Immunol Rev. 1999;168:121-130.
102. Rahman A, Tsai V, Goudreau A, et al. Specific depletion of human anti-adenovirus antibodies facilitates transduction in an in vivo model for systematic gene therapy. Mol Ther. 2001;1:15-25 (0016).
103. Lorence RM, Roberts MS, Groene WS, et al. Replication-competent, oncolytic Newcastle disease virus for cancer therapy. In: Driever PH, Roabkin SD, eds. Replication-Competent Viruses for Cancer Therapy. Basel, Switzerland: Karger (in press).
104. Li E, Stupack D, Bokoch GM, et al. Adenovirus endocytosis requires actin cytoskeleton organization mediated by Rho family GTPases. J Virol. 1998;72:8806-8812.
105. Wolff G, et al. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol. 1997;71:624-629.
106. Biewenga J, et al. Macrophage depletion in the rat after intraperitoneal administration of liposome-encapsulated clodronate: Depletion kinetics and accelerated repopulation of peritoneal and omental macrophages by administration of Freund's adjuvant. Cell Tissue Res. 1995;280:189-196.
107. McCuskey RS, McCuskey PA, Urbaschek R, et al. Kupffer cell function in host defense. Rev Infect Dis. 1999;9:S616-S619.
108. Huitinga L, et al. Macrophages in T-cell line-medicated demyelination and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats. Clin Exp Immunol. 1995;10: 344-351.
109. Laman JD, Kors N, van Rooijen N, et al. Mechanism of follicular trapping localization of immune complexes and cell remnants after elimination and repopulation of different spleen cell populations. Immunology. 1990:7157-7162.
110. Pinto AJ, Stewart D, van Rooijen N, et al. Selective depletion of liver and splenic macrophages using lyposomes encapsulating the drug dichloromethylene diphosphonate: Effects of antimicrobial resistance. J Leukoc Biol. 1991;49:579-586.
111. Qiam Q, Jutila A, van Rooijen N, et al. Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidates. J Immunol. 1994;152:5000-5008.
112. Tscaikowsky D, Brain JD. Effects of liposime-encapsulated dichloromethylene diphosphonate on macrophage function and endotoxin-induced mortality. Biochim Biophys Acta. 1994;1222:323-330.
113. Van Rooijen N. The liposome-mediated macrophage "suicide" technique. J Immunol Methods. 1989;124:1-6.
114. Van Rooijen N, Kors N, Kraal G. Macrophage subset repopulation in the spleen differential kinetics after liposome-mediated elimination. J Leukoc Biol. 1989;45:97-104.
115. Van Rooijen N, Kors N, van der ende M, et al. Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate. Cell Tissue Res. 1990;260:215-222.
116. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages mechanism of action preparation of lyposomes and application. J Immunol Methods. 1994;174:83-93.
117. Van Rooijen N, Sanders A. Kupffer cell depletion by liposome-delivered drugs: Comparative activity of intracellular clodronate propamidine and ethylenediaminetetraacetic acid. Hepatology. 1996;23:1239-1243.
118. Vreden SG. Kupffer cell elimination enhances development of liver schizonts of Plasmodium berghei in rats. Infect Immun. 1993;61:1936-1939.
119. Rahman A, Tsai V, Goudreau A, et al. Specific depletion of human anti-adenovirus antibodies facilitates transduction in an in vivo model for systematic gene therapy. Mol Ther. 2001;3:768-778.
120. Lechner MS, Mack DH, Finicle AB, et al. Human papilloma virus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J. 1992;11:3045-3052.
121. Gannon JV, Lane DP. P53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature. 1987;329: 456-458.
122. Goodrum FD, Omelles DA. The early region 1B 55-kilodalton oncoprotein of adenovirus relieved growth restrictions imposed on viral replication by the cell cycle. J Virol. 1997;71:548-561.
123. Hall AR, Dix BR, O'Carroll SJ, Braithwaite AW. P-53 dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med. 1998;4:1068-1072.
124. Tumell AS, Grand RJ, Gallimore PH. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J Virol. 1999;73:2074-2083.
125. Goodrum FD, Ornelles DA. P53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic injection. J Virol. 1998;72:9479-9490.
126. Harada J, Berk AJ. P53-independent and -dependent requirements for E1B-55 kD in adenovirus type 5 replication. J Virol. 1999;73:5333-5344.
127. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997;3:639-645.
128. Hall AR, Dix BR, O'Carroll SJ, et al. P-53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med. 1998;4:1068-1072.
129. Kirn D, Hermiston T, McCormick LF. ONYX-015: Clinical data are encouraging. Nat Med. 1998;4:1341-1342.
130. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is dependent of p53 status in tumor cells. J Virol. 1998;72:9470-9478.
131. De-Chau Yu, Sakamoto GT, Henderson DR. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 1999;59:1498-1504.
132. Habib NA, Mitry RR, Sarraf CE, et al. Assesment of growth inhibition and morphological changes in in vivo hepatocellular carcinoma models post treatment with dl1520 adenovirus. Cancer Gene Ther 2002;9:414-420.
133. Kenney S, Pagano JS. Viruses as oncolytic agents: A new age for "therapeutic" viruses? J Nat Cancer Inst. 1994;86:1185-1186.
134. Yang Y, Nunes FA, Berenscsi KM, Furth EE, Gonezol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA. 1994;91:4407-4411.
135. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55 kD gene deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res. 2000;60:6359-6366.
136. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication- selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 2001;19:289-298.
137. Habib N, Salama H, Abu Median AAEL, et al. Clinical trial E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther. 2002;9:254-259.
138. Khuri F, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adeno-virus, in combination with Cisplatin and 5-FU in patients with recurrent head and neck cancer. Nat Med. 2000;6:879-885.
139. Nemunaitis J, Cunningham C, Tong AW, et al. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther. (submitted for publication).
140. Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kD gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol. 2002;6:1562-1569.
141. Ganly I, et al. A phase I study of ONYX-015, and E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res. 2000;6:798-806.
142. Reid T, Galanis E, Abbruzzese J, et al. Intra-arterial 99 administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: Safety, feasibility and biological activity. J Clin Oncol. Proc Am Soc Clin Oncol. 2001;20:549.
143. Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase 1 trial. Gene Ther. 2001;8:308-315.
144. Scherer WF, Syverton JT, Gey GO. Studies on the propagation in vitro in vivo of poliomyelitis viruses: IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med. 1953;97:695-709.
145. Southam CM, Moore AE. Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus. Cancer. 1952:1025-1034.
146. Smith RR, Huebner JR, Rowe WP, Schatten WE, Thomas LB. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 1956;9:1211-1218.
147. Russell SJ. Replication vectors for gene therapy of cancer: Risks, limitations and prospects. Eur J Cancer. 1994;30A:1165-1171.
148. Asada T. A new attempt for cancer therapy. Jpn Red Cross Med J. 1963;16:9-19.
149. Asada T. Treatment of human cancer with mumps virus. Cancer. 1974;34:1907-1928.
150. Yamanishi E, Takahashi M, Kurimura T, Ueda S, Minekawa Y. Studies on live mumps virus vaccine. Biken J. 1970;13:157-161.
151. Csatary LK, Eckhardt S, Bukosza I, et al. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev. 1993;17:619-627.
152. Csatary LK, Gergely P. Virus vaccines for the treatment of cancer. Orv Hetil. 1990;131:2585-2588.
153. Shimizu Y, Hasumi K, Okudaira Y. Immunotherapy of advanced gynecologic cancer patients utilizing mumps virus. Cancer Detect Prev. 1988;12:487-495.
154. Okuno Y, Asada T, Yamanishi K. Studies on the use of mumps virus for treatment of human cancer. Biken J. 1978;21:37-49.
155. Freedman RS, Edwards CL, Bowen JM, et al. Viral oncolysates in patients with advanced ovarian cancer. Gynecol Oncol. 1988;29:337-347.
156. Cassel WA, Garrett RE. Relationship between viral neurotropism and oncolysis: II. Study of influenza virus. Cancer. 1967;20:440-444.
157. Heicappell R, Schirmacher V, Von Hoegen P. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells: I. Parameters for optional therapeutic effects. Int J Cancer. 1986;37:569-577.
158. Boone CW. Augmented immunogenicity of tumor cell homogenates infected with influenza virus. Recent Results Cancer Res. 1974;47:394-400.
159. Ionnides CG, Platsoucas CD, Patenia R, et al. T-cell functions in ovarian cancer patients treated with viral oncolysates: I. Increased helper activity to immunoglobulins production. Anticancer Res. 1990;10:645-654.
160. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 1994;54:3963-3966.
161. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgenes and augment cyclophosphamide chemotherapy. Nat Biotechnol. 1998;16: 444-448.
162. Boviatsis EJ, Scharf JM, Chase M, Harringtonowall NW, Breakfield XO, Chiocca EA. Antitumor activity and reporter gene transfer into rat brain or ribonucleotide reductase. Gene Ther. 1994:323-331.
163. Chou J, Kein E, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma, 34.5, a gene nonessential for growth in culture. Science. 1990;250:1262-1266 (Washington, DC).
164. Chou J, Roizman B. The y(34.5) gene of herpes simplex virus 1 precludes neoblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells. Proc Natl Acad Sci USA. 1992;89: 3266-3270.
165. McKie EA, Maclean AR, Lewis AD, et al. Selective in vitro replication of herpes simplex virus type (HSV-1) ICP34.5 null mutants in primary human CNS tumours - Evaluation of a potentially effective clinical therapy. Br J Cancer. 1996;74:745-752.
166. Martuza RL. Act locally, think globally. Nat Med. 1997;3:1323.
167. Alemany R, Gomez-Manzano C, Balague C, et al. Gene therapy for gliomas: Molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res. 1999;252:1-12.
168. Pennisi E. Will a twist of viral fate lead to anew cancer treatment? Science. 1996;274:342-343 (Washington, DC).
169. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1:938-943.
170. Chambers R, Gillespe GY, Soroceanu L, et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in SCID mouse model of human malignant glioma. Proc Natl Acad Sci USA. 1995;92:1411-1415.
171. Kesari S, Randazzo BP, Valyi-Nagy T, et al. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest. 1995;73:636-648.
172. Andreasky S, He B, Gillespe G, et al. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA. 1996;93:11313-11318.
173. Lambright E, Kang EH, Force S, et al. Effect of pre-existing anti-herpes immunity on the efficacy of herpes simplex virus therapy in a murine intraperitoneal tumor model. Mol Ther. 2000;2:387-393.
174. Randazzo BP, Bhat MG, Kesari S, Fraser NW, Brown SM. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J Invest Dermatol. 1997;108:933-937.
175. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication competent multimutated herpes simplex virus 1. Hum Gene Ther. 1998;9:2173-2185.
176. Toda M, Rabkin AD, Kojima H, Martuza RL. Herpes simplex virus as in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther. 1999;10:385-393.
177. Yoon SS, Carroll NM, Chiocca EA, Tanabe KK. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann Surg. 1998;228:366-374.
178. Coukus G, Makrigiannakis A, Kang EH, et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res. 1999;5:1523-1537.
179. Coukus G, Rubin SC, Molanr-Kimber KL. Application for recombinant herpes simplex virus-1 (HSV-1) for the treatment of malignancies outside the central nervous system. Gene Ther Mol Biol. 1999;3:79-89.
180. Lambright ES, Caparrelli D, Abbas A, et al. Oncolytic therapy using a mutant type 1 herpes simplex virus and the role of the immune response. Ann Thorac Surg. 1999;68:1756-1762.
181. Kucharzuk JC, Randazzo B, Elshami AA, et al. Use of a replication-restricted recombinant herpes virus to treat localized human malignancy. Cancer Res. 1997;57:466-471.
182. Toyozuimi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL. Combined therapy with chemotherapeutic agents and herpes simplex virus type-1 ICP34.5 mutant (HSC-1716) in human non-small lung cancer. Hum Gene Ther. 1999;10:3013-3029.
183. Advani SJ, Su-Mi Chung SY, Yan SY, et al. Replication competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res. 1999;59:2055-2058.
184. Carroll NM, Chiocca EA, Takahashi K, Tanabe KK. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg. 1996;224:323-329.
185. Papanastassiou V, Rampling R, Frase M, et al. The potential for efficacy of the modified (ICP 34.5) herpes simplex virus HSV1716 following intratumoral injection into human malignant glioma: A proof of principle study. Gene Ther. 2002;9:398-406.
186. Jorgensen TJ, Katz S, Wittmack EK, et al. Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia. 2001;3:451-456.
187. Spear MA, Sun F, Eling DJ, et al. Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide-reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Ther. 2000;7:1051-1059.
188. Advani SJ, Sibley GS, Song PY, et al. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors. Gene Ther. 1998;5:160-165.
189. Advani SJ, Su-Mi Ching SY, Yan SY, et al. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res. 1999;59:2055-2058.
190. Bradley JD, Kataoka Y, Advani S, et al. Ionizing radiation improves survival in mice bearing intracranial high grade gliomas injected with genetically modified herpes simplex virus. Clin Cancer Res. 1999;5:1517-1522.
191. Stephanie VB, Rubin SC, Coukus G, Amin KM, Albelda SM, Molnar-Kimber KL. Replication selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Hum Gene Ther. 2002;13:627-639.
192. Coukos G, Makrigiannakis A, Kang E, Rubin SC, Albelda SM, Molnar-Kimber KL. ICP34.5 deficient herpes simplex virus-1 kills ovarian cancer cells via non-apoptotic or p53-independent apoptotic death: Implications for chemotherapy-resistant disease. Clin Cancer Res. 2000;6:3342-3353.
193. Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther. 1999;10:3013-3029.
194. Endo T, Toda M, Watanabe M, et al. In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. Cancer Gene Ther. 2002;9:142-148.
195. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication- competent multimutated herpes simplex virus 1. Hum Gene Ther. 1998;9:2177-2185.
196. Toda M, Rabkin SD, Kojima H, et al. Herpes simplex virus as an in situ cancer vaccine for the induction of specific antitumor immunity. Hum Gene Ther. 1999;10:385-393.
197. Toda M, Martuza RL, Koima H, et al. In situ cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol. 1998;160:4457-4464.
198. Parker JN, Gillespie GY, Love CE, Randall S, Whitley RJ, Markert JM. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA. 2000:2208-2213.
199. Andreansky S, He B, van Cott J, et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 1998:121-130.
200. Toda M, Martuza RL, Kojima H, Rabkin SD. In situ cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systematic antitumor activity. J Immunol. 1998;160:4457-4464.
201. Pawlik TM, Nakamura H, Yoon SS, et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res. 2000;60:2790-2795.
202. Rodriguez R, Schuur ER, Yeong Lim H, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57:2559-2563.
203. DeWeese TL, van der Poel H, Li S, et al. A phase 1 trial of CV706, a replication-competent, PSA selective oncolytic adenovirus for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001;61: 7464-7472.
204. Chen Y, De Weese T, Dilley J, et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res. 2001;61:5453-5460.
205. Garzotto M, Haimovitz-Friedman A, Liao W-C, et al. Reversal radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res. 1999;59: 5194-5201.
206. Chen Y, De Weese T, Dilley J, et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res. 2001;61:5453-5460.
207. De-Chao Y, Chen Y, Seng M, Dilley J, Henderson DR. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 1999;59:4200-4203.
208. De-Chao Y, Chen Y, Dilley J, et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. 2001;61:517-525.
209. Li Y, De-Chao Y, Chen Y, Amin P, Zhang H, Henderson DR. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res. 2001;61:6428-6436.
210. Hallenbeck PL, Chang YN, Hay C, et al. A novel tumor specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther. 1999;10:1721-1733.
211. Khromykh AA. Replication-based vectors of positive strand RNA viruses. Curr Opin Mol Ther. 2000;2:555-569.
212. Seth A, Ourmanov I, Schmitz JE, et al. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J Virol. 2000;74: 2502-2509.
213. + T-cell immunity. J Virol. 2002;76:3791-3799.
214. Ramsay AJ, Kent SJ, Strugnell RA, Suhrbier A, Thomson SA, Ramshaw IA. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. Immunol Rev. 1999;171:27-44.
215. Gorse GJ, Patel GB, Belshe RB. HIV type-1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers. AIDS Res Hum Retrovir. 2001;17:1175-1189.
216. Rolph MS, Ramshaw IA. Recombinant viruses as vaccines and immunological tools. Curr Opin Immunol. 1997;9:517-524.
217. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392:86-89.
218. Ho LJ, Wang JJ, Shaio MF, et al. Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. J Immunol. 2001;166:1499-1506.
219. Johnston LJ, Halliday GM, King NJ. Langerhans cells migrate to local lymph nodes following cutaneous injection with an arbovirus. J Invest Dermatol. 2000;114:560-568.
220. Johnston LJ, Halliday GM, King NJ. Langerhans cell migrate to local lymph nodes following cutaneous infection with an arbovirus. J Invest Dermatol. 2000;114:560-568.
221. Libarty DH, Pichayangkul S, Ajariyakhajorn C, Endy TP, Ennis FA. Human dendritic cells are activated by dengue virus infection: Enhancement by gamma interferon and implications for disease pathogenesis. J Virol. 2001;75:3501-3508.
222. Wu SJ, Grougard-Vogel G, Sun W, et al. Human skin Langerhans cells are targets of dengue virus infection. Nat Med. 2000;6:816-820.
223. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-hematopoietic cells requires presentation of exogenous antigen. Nature. 1999;398:77-80.
224. Gardner JP, Prolov I, Perri S, et al. Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J Virol. 2000;74:11849-11985.
225. MacDonald GH, Johnston RE. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol. 2000;74:914-922.
226. Anduan T.
227. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces antiglioma effect in vivo. Oncogene. 2000;19:2-12.
228. Bayley ST, Mymryk JS. Adenovirus E1A proteins and transformation. Int J Oncol. 1994;5:425-444.
229. Howe JA, Bayley ST. Effects of Ad5E1A mutant viruses on the cell cycle in relation to the binding of cellular proteins including the retinoblastoma protein and cyclin A. Virology. 1992;186:15-24.
230. Howe JA, Mymryk JS, Egan C, Branton PE, Bayley ST. Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis. Proc Natl Acad Sci USA. 1990;87:5883-5887.
231. Wang HG, Draetta G, Moran E. E1A induces phosphorylation of the retinoblastoma protein independently of direct physical association between the E1A and retinoblastoma products. Mol Cell Biol. 1991;11:4253-4265.
232. Wang HG, Rikitake Y, Carter MC, et al. Identification of specific adenovirus E1A N-terminal residues critical to the binding of cellular proteins and to the control of cell growth. J Virol. 1993;67:476-488.
233. Dyson N, Buchkovich K, Whyte P, Harlow E. Cellular proteins that are targeted by DNA tumor viruses for transformation. Princess Takamatsu Symp. 1989;20:191-198.
234. Moran E. DNA tumor virus transforming proteins and the cell cycle. Curr Opin Genet Dev. 1993;3:63-70.
235. Dubensky TW Jr. (re-)Engineering tumor cell-selective replicating adenoviruses: A step in the right direction toward systematic therapy for metastatic disease. Cancer Cell. 2002;1:307-308.
236. Johnson L, Shen A, Boyle L, et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systematic antitumor agents. Cancer Cell. 2002;1:325-337.
237. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323-3330.
238. Schutz A, Oertli D, Marti WR, et al. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen. Cancer Gene Ther. 2001;8:655-661 (SP).
239. Tmiryasova TM, Chen B, Fodor I. Replication-deficient vaccinia virus gene therapy vector: Evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells. J Gene Med. 2001;3:468-477 (September-October).
240. Gomella LG, Mastranelo MJ, McCue PA, Maguire HC Jr, Mulholand SG, Lattime EC. Phase I study of intravesical vaccinia. virus as a vector for gene therapy of bladder cancer. J Urol. 2001;166:1291-1295 (October).
241. Wallack MK, Sivanandam M, Balch CM, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind multicenter vaccinia. melanoma oncolysate trial. J Am Coll Surg. 1998;187:69-77.
242. Mastrangelo MJ, Maguire HC Jr, Eisiniohr LC, et al. Intratumoral recombinant GM-CSF-encoding virus to package amplicons containing cytokine gene therapy vector in cancer, persistent transgene expression despite antibody generation. Cancer Gene Ther. 2000;7:663-670.
243. Naik AM, Xu H, Alexander HR, et al. A mutant vaccinia. virus with improved tumor selectivity. Proceedings of the 54th Annual SSO Cancer Symposium. 2001:40a.
244. Coffey MC, Strong JE, Forsyth PA, et al. Reovirus therapy of tumors with activated Ras pathway. Science. 1998;282:1332-1334.
245. Hirasawa K, Yoon C, Sishikawa SG, et al. Reovirus therapy of metastatic cancer models in immune-competent mice. Proc Am Assoc Cancer Res. 2001;42:2427a.
246. Hirasawa K, Nishikawa SG, Norman KI, et al. Oncolytic reovirus against ovarian and colon cancer. Cancer Res. 2002;62:1696-1701 (March 15).
247. Robert MS, Lorence RM, Gronen WS, et al. Treatment of neoplasms with viruses. International Patent Publication No. Wo 99/18799. 1999.
248. Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6:821-825.
249. Schirrmacher V, Ahlert T, Probstle T, et al. Immunization with virus-modified tumor cells. Semin Oncol. 1998;25: 677-696.
250. Batliwalla FM, Bateman BA, Serrano D, et al. A 15 year follow up of AJCC stage 3 malignant melanoma patients treated post surgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med. 1998;42:2441a.
251. Lorence RM, Robert MS, Gronen WS, et al. Replication competent, oncolysate Newcastle disease virus for cancer therapy. In: Hernaiz DP, Rabkin SD, eds. Replication-Competent Viruses for Cancer Therapy. Monographs in Virology. Basel, Switzerland: Karger; 2001:160-182 (Vol. 22).
252. Lorence RM, Roberts MS, Gronene WS, et al. Regression of human tumor xenografts following intravenous treatment using PV701, a naturally attenuated oncolytic strain of Newcastle disease virus. Proc Am Assoc Cancer Res. 2001;42:454 (Abstract 2442).
253. Lorence RM, Katubig BB, Reichard KW, et al. Complete regression of human neoblastoma xenographs in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst. 1994;86:1228-1233.
254. Lorence RM, Katubig BB, Reichard KW, et al. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res. 1994;54:6017-6021.
255. Cassel WA, Garrett RE. Newcastle disease virus as antineoplastic agent. Cancer. 1965;18:863-868.
256. Pecor AL, Rizvi N, Gary L, et al. Phase I trial of Intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol. 2002;20: 2251-2266.